image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

SEC Filing Details

Document Details

Form
4
Filing Date
January 30, 2024
Document Date
January 30, 2024
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Nurix Therapeutics, Inc.
Issuer
NURIX THERAPEUTICS, INC.
Filer
HANSEN GWENN
Print Page
Email Alerts
RSS Feeds
Contact IR